GlassScriptPhysician profile
Dilipkumar N Patel
NPI 1215903281
$4,060.67
in general payments reported to CMS, 2019-2025
27 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $117 · 2021: $116 · 2022: $285 · 2023: $1,304 · 2024: $868 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Consulting Fee: $800 · Education: $39.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.30 |
| Consulting Fee | $800.00 |
| Education | $39.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $800.00 | 2023 | |
| Janssen Biotech, INC. | $571.78 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $536.44 | 2019-2025 | |
| Pfizer INC. | $370.78 | 2019-2025 | |
| Gilead Sciences, INC. | $358.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.37 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.57 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $113.56 | 2019-2021 | |
| Genzyme Corporation | $111.85 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $104.97 | 2025 | Iqirvo |
| Qol Medical, LLC | $94.70 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $84.34 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $76.98 | 2019-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $72.62 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $72.50 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $59.77 | 2024 | Zymfentra, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.05 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $39.97 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $38.37 | 2022-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $38.16 | 2023 | Idacio |
| Redhill Biopharma INC. | $37.94 | 2022 | |
| Celgene Corporation | $33.31 | 2024 | Zeposia |
| Lilly USA, LLC | $29.30 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $27.08 | 2024 | |
| Nestle Healthcare Nutrition INC. | $23.40 | 2022 | |
| Merck Sharp & Dohme LLC | $19.18 | 2019 | |
| Shire North American Group INC | $14.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilipkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.